Previous 10 | Next 10 |
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exerci...
Ra Pharmaceuticals (NASDAQ: RARX ) has announced it plans to offer $100M in common stock in an underwritten public offering. More news on: Ra Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...
Ra Pharmaceuticals (NASDAQ: RARX ) inks a global license agreement with Camurus AB ( OTC:CAMRF ) securing the rights to the latter's FluidCrystal technology that will enable the development of a long-acting formulation of C5 inhibitor zilucoplan for the treatment of complement-mediated dis...
FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing Ra Pharmaceuticals, Inc. (Nasdaq:RARX) and Camurus AB (Nasdaq STO:CAMX) today announced a...
I’ve been pleased with how Ra Pharmaceuticals ( RARX ) has navigated the clinical program changes over the last 12 months. The stock is up quite a bit since I wrote a positive piece almost a year ago, though I have watched the stock deliver the gains from the sidelines. Most, if not...
The following slide deck was published by Ra Pharmaceuticals, Inc. in conjunction with this Read more ...
Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
News, Short Squeeze, Breakout and More Instantly...
Ra Pharmaceuticals Inc. Company Name:
RARX Stock Symbol:
NASDAQ Market:
Ra Pharmaceuticals Inc. Website:
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...
Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...